Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,688.00 | 35.50 | -0.41% |
| CAC 40 | 7,589.66 | 36.21 | 0.48% |
| DAX 40 | 23,350.55 | 293.17 | 1.27% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,774.65 | 17.15 | -0.20% |
| HKSE | 23,657.85 | 127.37 | 0.54% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,354.09 | 49.14 | -0.13% |
| NZX 50 Index | 12,532.65 | 36.40 | -0.29% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,474.90 | 30.60 | -0.36% |
| SSE Composite Index | 3,382.01 | 22.12 | 0.66% |